Clover Biopharmaceuticals Launches Phase 2 Trial for Novel Combination Vaccine Against RSV, hMPV, and PIV3 Clover Biopharmaceuticals has initiated a Phase 2 clinical trial for its innovative combination vaccine targeting RSV, hMPV, and PIV3, promising a significant leap in respiratory disease prevention.

Clover Biopharmaceuticals Launches Phase 2 Trial for Novel Combination Vaccine Against RSV, hMPV, and PIV3 #Shanghai #Australia #RSV_Vaccine #Phase_2_Trial #Clover_Biotech